Pharming Projects 8-13% Revenue Growth in 2026 Amid Rare Disease Pipeline Push
Event summary
- Pharming Group N.V. forecasts 2026 revenue of $405–425M (8-13% growth) driven by Joenja® and RUCONEST®
- Operating expenses projected at $330–335M, primarily due to R&D for leniolisib and napazimone (KL1333) trials
- Leniolisib Phase II trials in broader PID populations expected to report top-line data in H2 2026
- Napazimone (KL1333) pivotal FALCON trial on track for 2027 readout
- Investor Day featured presentations from clinical experts Jocelyn Farmer and Amel Karaa
The big picture
Pharming's 2026 guidance reflects confidence in its commercial portfolio while betting heavily on two high-potential pipeline programs targeting large, underserved rare disease populations. The company is positioning itself as a leader in PID and mitochondrial disease treatments, areas with significant unmet medical need. Success in these areas could drive long-term value creation, but requires sustained investment and positive clinical outcomes.
What we're watching
- Pipeline Expansion
- Whether leniolisib's expansion into broader PID populations can replicate its success in APDS
- Regulatory Milestones
- The pace at which napazimone (KL1333) progresses through its pivotal trial and potential approval timeline
- Financial Discipline
- How Pharming balances aggressive R&D investment with maintaining projected revenue growth
Related topics